Table 3.
Primary and Secondary Outcomes Before Propensity Matching.
| Overall (N = 897) | Protamine Full (N = 706) | Protamine Half (N = 191) | p-Value | |
|---|---|---|---|---|
| Primary | ||||
| Combined endpoint | 79 (8.8%) | 50 (7.1%) | 29 (15.2%) | <0.001 |
| In-hospital mortality | 37 (4.1%) | 26 (3.7%) | 11 (5.8%) | 0.200 |
| Life-threatening bleeding | 23 (2.5%) | 14 (2%) | 9 (4.7%) | 0.034 |
| Major bleeding | 28 (3.1%) | 16 (2.3%) | 12 (6.3%) | 0.005 |
| Major vascular complications | 37 (4.1%) | 25 (3.5%) | 12 (6.3%) | 0.091 |
| Secondary | ||||
| Stroke after TAVI | 15 (1.7%) | 11 (1.6%) | 4 (2.1%) | 0.608 |
| Myocardial Infarction | 3 (0.003%) | 2 (0.002%) | 1 (0.005%) | 0.610 |
| Minor bleeding | 124 (13.8%) | 87 (12.2%) | 37 (19.5%) | 0.01 |
| Minor vascular complications | 204 (22.7%) | 157 (22.2%) | 48 (25.1%) | 0.235 |
| In-hospital stay (days) | 17.1 ± 14.1 | 15.9 ± 12.7 | 21.7 ± 17.6 | <0.001 |
| Blood transfusion volume (units) | 0.7 ± 2.0 | 0.5 ± 1.6 | 1.1 ± 3.1 | <0.001 |